South Korea Biotech Gets First Commercial Order To Clone Dog
This article was originally published in PharmAsia News
RNL Bio, a biotechnology company in South Korea, now has an order to clone a pet animal as the beginning of a commercial service that could begin next year. RNL Bio is affiliated with the research laboratory of Seoul National University's stem-cell facility that produced the first cloned dog three years ago. The first commercial order for a clone came from a California woman who wants to use material from her late pit bull terrier. RNL Bio plans to charge about $150,000 per clone. (Click here for more - a subscription may be required
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.